Abstract: The invention relates to a pharmaceutical product or container closure system containing an overpouch with an intransparent first foil and a transparent second foil, a transparent primary container for holding a transparent liquid, e.g., a pharmaceutical formulation, wherein the transparent primary container is packed within the overpouch and labeled with at least one label and wherein the at least one label acts as a light absorbing segment having a reflection RL for light in the range of about 350 nm to about 800 nm and an inner surface of the intransparent first foil of the overpouch acts as a light reflecting background having a reflection RF for light in the direction of the primary container in the range of about 350 nm to about 800 nm with RF?RL. By the transparent second foil and the inventive reflection properties it is achieved that the at least one label on the primary container is visible and readable. Additionally, visual inspection of the content of the transparent primary container is possible.

Abstract: The invention relates to a pharmaceutical product or container closure system containing an overpouch with an intransparent first foil and a transparent second foil, a transparent primary container for holding a transparent liquid, e.g., a pharmaceutical formulation, wherein the transparent primary container is packed within the overpouch and labeled with at least one label and wherein the at least one label acts as a light absorbing segment having a reflection RL for light in the range of about 350 nm to about 800 nm and an inner surface of the intransparent first foil of the overpouch acts as a light reflecting background having a reflection RF for light in the direction of the primary container in the range of about 350 nm to about 800 nm with RF?RL. By the transparent second foil and the inventive reflection properties it is achieved that the at least one label on the primary container is visible and readable. Additionally, visual inspection of the content of the transparent primary container is possible.

Abstract: The invention relates to a pharmaceutical product or container closure system containing an overpouch with an intransparent first foil and a transparent second foil, a transparent primary container for holding a transparent liquid, e.g., a pharmaceutical formulation, wherein the transparent primary container is packed within the overpouch and labeled with at least one label and wherein the at least one label acts as a light absorbing segment having a reflection RL for light in the range of about 350 nm to about 800 nm and an inner surface of the intransparent first foil of the overpouch acts as a light reflecting background having a reflection RF for light in the direction of the primary container in the range of about 350 nm to about 800 nm with RF?RL. By the transparent second foil and the inventive reflection properties it is achieved that the at least one label on the primary container is visible and readable. Additionally, visual inspection of the content of the transparent primary container is possible.

Abstract: The invention relates to a pharmaceutical product or container closure system containing an overpouch with an intransparent first foil and a transparent second foil, a transparent primary container for holding a transparent liquid, e.g., a pharmaceutical formulation, wherein the transparent primary container is packed within the overpouch and labeled with at least one label and wherein the at least one label acts as a light absorbing segment having a reflection RL for light in the range of about 350 nm to about 800 nm and an inner surface of the intransparent first foil of the overpouch acts as a light reflecting background having a reflection RF for light in the direction of the primary container in the range of about 350 nm to about 800 nm with RF?RL. By the transparent second foil and the inventive reflection properties it is achieved that the at least one label on the primary container is visible and readable. Additionally, visual inspection of the content of the transparent primary container is possible.

Abstract: The current invention relates to new HIV-1 group O antigens, nucleic acids encoding them, and the use of said antigens and/or nucleic acids as reagents in the diagnosis and prophylaxis of AIDS. It also relates to new HIV-1 group O strains comprising these antigens.

Abstract: The claimed invention relates to an HIV-1 group O envelope antigen comprising SEQ ID NO: 100, and the use of said antigen as a reagent in the diagnosis of HIV-1 group O infection, and a kit therefore.

Abstract: The present invention relates to a retrovirus isolated from a chimpanzee and designated as SIV.sub.cpz-ant and to variants of this virus, having the following essential morphological and immunological properties: the virus exhibits a tropism for T4 lymphocytes, the virus does not exhibit cytopathic effect with the formation of giant cells in the lymphocytes that it infects, the virus has a diameter of approximately 130 nm, the virus possesses a magnesium dependent reverse transcriptase activity, it can be cultivated in T4 receptor-bearing immortalized cell-lines, lysates of the virus containing a p27 protein that is immunologically distinct from the p25 of HIV-1 and p19 protein of HTLV-1 on Western Blot, lysates of the virus containing a gp140 protein which is immunologically distinct from the gp120 of HIV-1 and gp140 of HTLV-1 by Western Blot analysis, the lysate of the virus contains an additional transmembrane glycoprotein with a molecular weight of 44,000 to 50,000 kD.

Abstract: A new strain of Human Immunodeficiency Virus (HIV), which is the major etiological agent of Acquired Immune Deficiency Syndrome (AIDS), is identified. The new strain, products derived from the new strain, a diagnostic method for detecting antibodies to the strain in biological fluids, and a diagnostic kit for carrying out the method are described.